• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    3/1/23 12:31:13 PM ET
    $ADMP
    $ALHC
    $CDTX
    $FIGS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Health Care
    Get the next $ADMP alert in real time by email

    Gainers

    • Reata Pharmaceuticals (NASDAQ:RETA) stock moved upwards by 178.0% to $86.65 during Wednesday's regular session. The current volume of 10.1 million shares is 1012.6% of Reata Pharmaceuticals's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $3.1 billion.
    • OncoSec Medical (NASDAQ:ONCS) stock moved upwards by 92.59% to $2.08. Trading volume for this security as of 12:30 EST is 58.4 million, which is 7655.3% of its average full-day volume over the last 100 days. The company's market cap stands at $6.1 million.
    • BiomX (AMEX:PHGE) stock increased by 48.84% to $0.6. Trading volume for BiomX's stock is 1.7 million as of 12:30 EST. This is 353.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $21.4 million.
    • SCYNEXIS (NASDAQ:SCYX) shares increased by 27.51% to $1.9. Trading volume for this security as of 12:30 EST is 584.2K, which is 532.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $62.0 million.
    • Cidara Therapeutics (NASDAQ:CDTX) shares rose 24.39% to $1.88. As of 12:30 EST, Cidara Therapeutics's stock is trading at a volume of 3.1 million, which is 212.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $134.5 million.
    • Windtree Therapeutics (NASDAQ:WINT) stock rose 22.05% to $7.67. Trading volume for Windtree Therapeutics's stock is 687.5K as of 12:30 EST. This is 854.3% of its average full-day volume over the last 100 days. The company's market cap stands at $6.6 million.

    Losers

    • Novavax (NASDAQ:NVAX) stock decreased by 25.5% to $6.89 during Wednesday's regular session. The current volume of 17.5 million shares is 247.8% of Novavax's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $586.1 million. As per the press release, Q4 earnings came out yesterday.
    • FIGS (NYSE:FIGS) stock declined by 23.89% to $7.01. As of 12:30 EST, this security is trading at a volume of 10.1 million shares, making up 278.9% of its average full-day volume over the last 100 days. The company's market cap stands at $1.1 billion. As per the news, the Q4 earnings report came out yesterday.
    • Adamis Pharmaceuticals (NASDAQ:ADMP) shares decreased by 23.76% to $0.17. The current volume of 5.0 million shares is 563.0% of Adamis Pharmaceuticals's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $25.7 million.
    • Invitae (NYSE:NVTA) shares decreased by 21.17% to $1.7. Trading volume for Invitae's stock is 23.5 million as of 12:30 EST. This is 293.3% of its average full-day volume over the last 100 days. The company's market cap stands at $411.7 million. As per the news, the Q4 earnings report came out yesterday.
    • Alignment Healthcare (NASDAQ:ALHC) stock decreased by 18.16% to $8.13. As of 12:30 EST, Alignment Healthcare's stock is trading at a volume of 940.2K, which is 135.1% of its average full-day volume over the last 100 days. The company's market cap stands at $1.5 billion. As per the news, the Q4 earnings report came out yesterday.
    • Rubius Therapeutics (NASDAQ:RUBY) shares fell 17.76% to $0.12. Trading volume for Rubius Therapeutics's stock is 4.7 million as of 12:30 EST. This is 153.7% of its average full-day volume over the last 100 days. The company's market cap stands at $10.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADMP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADMP
    $ALHC
    $CDTX
    $FIGS

    CompanyDatePrice TargetRatingAnalyst
    FIGS Inc.
    $FIGS
    3/20/2026$22.00Perform → Outperform
    Oppenheimer
    FIGS Inc.
    $FIGS
    2/27/2026$17.00Sector Weight → Overweight
    KeyBanc Capital Markets
    FIGS Inc.
    $FIGS
    2/27/2026$9.00 → $15.00Market Perform
    Telsey Advisory Group
    Alignment Healthcare Inc.
    $ALHC
    11/24/2025$20.00Neutral → Overweight
    Analyst
    Cidara Therapeutics Inc.
    $CDTX
    11/17/2025Overweight → Equal-Weight
    Morgan Stanley
    Cidara Therapeutics Inc.
    $CDTX
    11/17/2025Overweight → Neutral
    Analyst
    Cidara Therapeutics Inc.
    $CDTX
    11/17/2025Outperform → Sector Perform
    RBC Capital Mkts
    FIGS Inc.
    $FIGS
    11/7/2025$7.00 → $9.00Market Perform
    Telsey Advisory Group
    More analyst ratings

    $ADMP
    $ALHC
    $CDTX
    $FIGS
    SEC Filings

    View All

    BiomX Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

    8-K - BiomX Inc. (0001739174) (Filer)

    3/27/26 4:50:53 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Novavax Inc.

    SCHEDULE 13G/A - NOVAVAX INC (0001000694) (Subject)

    3/27/26 11:06:41 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by FIGS Inc.

    SCHEDULE 13G/A - FIGS, Inc. (0001846576) (Subject)

    3/26/26 6:20:59 PM ET
    $FIGS
    Apparel
    Consumer Discretionary

    $ADMP
    $ALHC
    $CDTX
    $FIGS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    October 3, 2023 - FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants

    For Immediate Release: October 03, 2023 Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. Individuals 12 years of age and older previously vaccinated with a COVID-19 vaccine (and who have not already been vaccinated with a recently updated mRNA CO

    10/3/23 2:56:27 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ADMP
    $ALHC
    $CDTX
    $FIGS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    FIGS, Inc. upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded FIGS, Inc. from Perform to Outperform and set a new price target of $22.00

    3/20/26 8:28:51 AM ET
    $FIGS
    Apparel
    Consumer Discretionary

    FIGS, Inc. upgraded by KeyBanc Capital Markets with a new price target

    KeyBanc Capital Markets upgraded FIGS, Inc. from Sector Weight to Overweight and set a new price target of $17.00

    2/27/26 8:21:04 AM ET
    $FIGS
    Apparel
    Consumer Discretionary

    Telsey Advisory Group reiterated coverage on FIGS, Inc. with a new price target

    Telsey Advisory Group reiterated coverage of FIGS, Inc. with a rating of Market Perform and set a new price target of $15.00 from $9.00 previously

    2/27/26 8:07:13 AM ET
    $FIGS
    Apparel
    Consumer Discretionary

    $ADMP
    $ALHC
    $CDTX
    $FIGS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BiomX Inc. Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency

    NETANYA, Israel, March 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) (the "Company") today announced that on March 25, 2026, the Company received a notice from the staff of NYSE American LLC (the "NYSE American") that the Company was not in compliance with the NYSE American's continued listing standards in Part 10, Section 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide (the "Company Guide"), requiring a company to have stockholders' equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, Section 1003(a)(ii) of the Company Guide requiring a company to have stockholders' equity

    3/27/26 4:30:00 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Launches Security Subsidiary in Israel and Will Initially Invest Over $3 million In Its Operations

    NETANYA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) today announced the launch of X Security & Defense LTD., a new wholly-owned subsidiary. The company will finance its 2026 operations with over $3 million from internal funds, including for operations and acquisitions related to security, defense and first response. For its initial transaction, BiomX has signed a non-binding LOI with an unrelated third party to secure the exclusive distribution rights in Israel for an advanced aerial firefighting system from a drone components and payload developer. The proposed license would grant X Security & Defense the rights to distribute drone-based fire suppression solutions,

    3/26/26 8:48:01 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX CEO Issues Letter to Stockholders

    CEO Letter to Stockholders highlights the Company's strategic and financial reset designed to strengthen BiomX in the near term and unlock future growth opportunitiesDOVER, Del., March 19, 2026 /PRNewswire/ -- BiomX Inc. (NYSE:PHGE), today released the following letter from its Chief Executive Officer to stockholders. Dear Stockholders,Over the past several weeks, BiomX has taken decisive steps to reshape its leadership, priorities, and financial structure. Leadership has evolved, strategic priorities have been sharpened, and we are taking concrete steps intended to improve the Company's financial and operational structure. These changes have not been easy, but they are necessary to put Biom

    3/19/26 9:15:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMP
    $ALHC
    $CDTX
    $FIGS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Stein Jeffrey disposed of $339,040 worth of shares (5,190 units at $65.33), bought $339,040 worth of shares (4,262 units at $79.55), gifted 1,873 shares and received a gift of 937 shares, decreasing direct ownership by 44% to 5,763 units (SEC Form 4)

    4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)

    1/7/26 8:12:25 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Ra Capital Management, L.P. bought $99,999,988 worth of shares (2,272,727 units at $44.00) (SEC Form 4)

    4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)

    6/30/25 4:56:56 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Mineo Chrysa bought $73,896 worth of shares (3,320 units at $22.26) (SEC Form 4)

    4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)

    6/4/25 4:23:24 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMP
    $ALHC
    $CDTX
    $FIGS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Kao John E

    4 - Alignment Healthcare, Inc. (0001832466) (Issuer)

    3/23/26 5:36:50 PM ET
    $ALHC
    Medical Specialities
    Health Care

    SEC Form 4 filed by Burzacchi Sebastian

    4 - Alignment Healthcare, Inc. (0001832466) (Issuer)

    3/19/26 6:44:17 PM ET
    $ALHC
    Medical Specialities
    Health Care

    SEC Form 4 filed by Kim Hyong

    4 - Alignment Healthcare, Inc. (0001832466) (Issuer)

    3/19/26 6:42:24 PM ET
    $ALHC
    Medical Specialities
    Health Care

    $ADMP
    $ALHC
    $CDTX
    $FIGS
    Leadership Updates

    Live Leadership Updates

    View All

    FIGS-Developed Healthcare is Human Act Introduced in Congress to Provide Federal Tax Credit for Healthcare Professionals

    Bipartisan legislation sponsored by Rep. Claudia Tenney (R-NY) and Rep. Steven Horsford (D-NV) recognizes healthcare professionals for their extraordinary sacrifices and addresses understaffing and burnout FIGS, Inc. (NYSE:FIGS), the global leading healthcare apparel brand, announced the introduction of the Healthcare is Human Act, a milestone bipartisan bill sponsored by Representatives Claudia Tenney (R-NY) and Steven Horsford (D-NV). Developed in partnership with FIGS, the Tenney-Horsford legislation provides a federal tax credit of up to $6,000 per year to healthcare professionals serving communities most impacted by shortages — directly addressing low pay as a driver of burnout, turn

    3/13/26 1:00:00 PM ET
    $FIGS
    Apparel
    Consumer Discretionary

    BiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of Growth

    Seasoned financial leaders join BiomX to support strategic execution and advancement of the companyDOVER, Del. and NESS ZIONA, Israel, March 9, 2026 /PRNewswire/ -- BiomX Inc. (NYSE:PHGE), a clinical-stage company developing natural and engineered phage therapies designed to target and destroy harmful bacteria in chronic diseases, today announced the appointment of Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer. Oster brings extensive experience in corporate strategy, mergers and acquisitions, and operational leadership across capital-intensive industries including energy, infrastructure, and industrial sectors. Throughout his career, he has led complex

    3/9/26 9:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Employ Inc. Appoints Jerry Jao as CEO

    DENVER, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Employ Inc., a leading provider of people-first, intelligent hiring solutions across JazzHR, Lever, and Jobvite, today announced the appointment of Jerry Jao as CEO. Jao is a successful serial entrepreneur who founded three businesses, including the AI-powered marketing and personalization SaaS company ReSci (Retention Science), acquired by Constant Contact in 2020. During his executive career, he first encountered Employ as a Lever customer and spent six years using the platform, gaining firsthand insight into how its innovation helps hiring managers stay organized and save time across the hiring process. Jao shared, "Hiring has never needed to

    2/18/26 8:00:00 AM ET
    $FIGS
    Apparel
    Consumer Discretionary

    $ADMP
    $ALHC
    $CDTX
    $FIGS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/9/24 5:37:15 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/4/24 4:15:14 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/3/24 4:34:49 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMP
    $ALHC
    $CDTX
    $FIGS
    Financials

    Live finance-specific insights

    View All

    FIGS Releases Fourth Quarter and Full Year 2025 Financial Results

    Exceeded Top and Bottom Line Expectations Grew Q4 2025 Net Revenues 33.0% to a Record $201.9 Million Achieved Q4 2025 Net Income Margin of 9.2% and Adjusted EBITDA Margin of 13.2% Plans Low Double-Digit Net Revenues Growth and Margin Expansion in FY 2026 FIGS, Inc. (NYSE:FIGS) (the "Company"), the global leading healthcare apparel brand dedicated to improving the lives of healthcare professionals, today released its fourth quarter and full year 2025 financial results and published a financial highlights presentation on its investor relations website at ir.wearfigs.com/financials/quarterly-results/. Fourth Quarter 2025 Financial Highlights Net revenues were $201.9 million, an in

    2/26/26 4:05:00 PM ET
    $FIGS
    Apparel
    Consumer Discretionary

    Alignment Healthcare Reports Fourth Quarter and Full-Year 2025 Results; Beats High-End of Guidance Across All Key Metrics

    Delivers full-year revenue of $3.95 billion, representing 46.1% growth year-over-year Exceeds high-end of fourth quarter and full-year guidance across all key metrics: membership, revenue, adjusted gross profit and adjusted EBITDARaises health plan membership guidance by 2,000 at the midpoint and introduces 2026 revenue guidance of $5.14 billion to $5.19 billion, representing 30%-31% growth year-over-year, and adjusted EBITDA of $133 million to $163 millionEarns recognition on the 2026 Fortune World's Most Admired Companies™ list, underscoring the company's innovative approach to senior health care ORANGE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ:ALHC),

    2/26/26 4:01:00 PM ET
    $ALHC
    Medical Specialities
    Health Care

    Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areasMultiple Material Transfer Agreements signed in 2025 and Q1 2026 with pharmaceutical companies, including major global pharmaceutical companies exploring the utility of Matrix-M for their vaccine portfolios Successful execution of Sanofi partnership with $225 million in milestones earned in full year 2025Total revenue of $147 million in the fourth quarter of 2025 and $1.1 billion for the full year 2025Continued advancement of early-stage pipeline with the intention to enter the clinic as early as 2027Year end 2025 Cash of $751 million Novavax exceeded its full year 2025 R&

    2/26/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care